Introduction
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Classical swine fever virus (CSFV) belongs to the genus Pestivirus within the family Flaviviridae Classical swine fever (CSF) has a tremendous impact on animal health and the pig industry. age classes of animals and severe neurological signs within 7 to 10 days [8] . The economic losses 17 caused by an outbreak in the Netherlands in 1997 were as high as 2.3 billion USD, and more than 18 11 million pigs had to be destroyed. When pigs are infected with CSFV strains that have recently 19 circulated in Europe, they become severely ill, and up to 90% die within 4 weeks after infection 20 [9] . Additionally, infected pork and pork products are dangerous sources for the spread of CSF.
21
Strategies to control CSFV mainly consist of a systematic prophylactic vaccination policy 22 and a non-vaccination stamping-out policy [10] . In 2016, 22 countries officially reported 23 mandatory vaccination campaigns (OIE WAHIS). Compulsory vaccination is the current policy in 24 China, and vaccination coverage must be over 90% at any time of the year in the swine population 1 [11] . Despite efforts by many government authorities to stamp out the disease from national pig 2 populations, the disease remains widespread in some regions [10, 12] and seems to be waiting for 3 the reintroduction and the next round of disease outbreaks. These highlight the necessity and 4 urgency of developing more effective approaches to eradicate the challenging CSFV. An alternative 5 strategy is to develop TG pigs that are genetically resistant to CSFV infection.
6
The rapid development of genome editing technologies has facilitated studies that explore specific 7 gene functions and the establishment of animal models. Recently, the production of genetically 8 modified animals with viral resistance by versatile CRISPR/Cas9 has been examined by several 9 researchers [13, 14] . In livestock, these technologies have contributed to the development of antiviral 10 animals and have provided obvious productivity benefits to producers, as well as welfare to the animals.
11
RNAi is a natural post-transcriptional gene silencing mechanism [15] , and since its discovery, RNAi 12 has been regarded by virologists as a promising method for the suppression of viral infection [16] [17] [18] [19] .
13
To date, the number of reported RNAi-based studies on CSFV suppression in vitro is large, and 14 these studies suggest that developing shRNA-TG pigs that are resistant to viral challenge may be 15 possible.
16
Therefore, in this study we aimed to combine CRISPR-Cas9 and RNAi technology to 20 Results
21
Selection of antiviral siRNA and shRNA knock-in cell lines 1
We first aimed to select small interference RNAs (siRNAs) that could efficiently inhibit CSFV.
2 Ten siRNAs (Table 1) Next, these two shRNA targeting donor vectors were separately electroporated into porcine 11 foetal fibroblasts (PFFs) with the CRISPR/Cas9 vector, shRNA knock-in PFFs were selected with 12 the limiting dilution method, and the knock-in events were confirmed by PCR with specific 
19
we selected shRNA knock-in PK-15 cells, another porcine cell line that was more susceptible to 20 CSFV infection. As expected, the viral challenge assay of these PK-15 clones showed comparable 21 antiviral ability to that of the PFF clones ( Fig. 1C and S4C Fig) . These results suggested an obvious 22 role for shRNA in inhibiting CSFV growth in these shRNA knock-in cell clones.
1
To assess potential toxicity caused by shRNA and the further feasibility of generating TG pigs 2 via SCNT, these two shRNA knock-in PFF lines were used as the donor cells for SCNT [24] . The 3 results indicated that the blastocyst development rates were similar between the TG group and 4 wild-type (WT) group (Table 3 ), suggesting that these knock-in PFFs could be further used to 5 generate anti-CSFV TG pigs via SCNT. 
Generation of TG offspring and analysis of heredity stability
3 When the TG founders were sexually mature, we obtained 11 F1-generation piglets by crossing 4 the TG founders with WT pigs. Of these piglets, 6 were TG offspring and 5 were NTG offspring 5 ( Fig. 3A, B ). The TG pigs possessed a stable shRNA gene copy number (S6A Fig the sex and positive rate of the newborn piglets showed no deviation from 8 the Mendelian law of inheritance. Interestingly, we also found that the molecular beacon could be 9 used to identify the differences in the expression level of the target siRNA between the TG pigs 10 and NTG pigs (S7 Fig) and that the expression pattern of the target siRNA in the F1-generation TG 11 pigs was similar to that of their female mother.
12
Importantly, we compared the expression level of the target siRNA between the TG founders 13 and their TG offspring, and the results indicated that there was no significant difference in the 14 shRNA expression level between the F0-and F1-generation TG pigs ( Fig. 3C ). Moreover, the 15 viral challenge assay showed that the antiviral ability of the parental TG cells was similar to that 
TG pigs resisted CSFV infection
21
CSF is an acute and highly contagious disease in pigs. In most cases of natural infection, CSFV is 22 mainly transmitted by direct contact with infected animals or by indirect spread via infected feces, 1 food, or carcasses [9] . Therefore, we decided to perform animal challenge experiments in an 2 "in-contact" infectious way. Next, all of the pigs were randomly distributed into two separate 3 rooms, and each room included one non-TG pig that was used to inject CSFV (NTG-In), three 4 NTG pigs and three TG pigs ( Fig. 4A ). Prior to the viral challenge, all pigs were tested for several 5 common pig-associated viruses (Table 4 ) and CSFV specific antibody. After three days of 6 acclimation, these NTG-In pigs were directly challenged with CSFV by intramuscular injection, 10 in the challenge test were monitored and recorded daily. Results showed that all of the NTG pigs 11 developed typical signs of CSFV infection, mortality was 100%. Although CSFV-associated 12 clinical symptoms were also observed in the TG pigs, which were not serious, and the virus levels 13 in the blood were lower in the TG pigs than in the NTG pigs.
14 As early as 1 day post-infection (dpi), all of the injected NTG-In pigs developed inappetence, 15 lethargy, and severe diarrhea and fever symptoms. The two injected NTG-In pigs died directly 16 from the infection at 7 dpi, and all of the NTG pigs died between 10 and 13 dpi. By contrast, all of 17 the TG pigs remained alive until euthanasia ( Fig. 5A ). Additionally, we investigated the body 18 temperatures and daily body weights of these challenged pigs. Compared to the TG pigs, these 19 NTG pigs exhibited more severe fever symptoms ( Fig. 5B ) and slower weight gain ( Fig. 5C ).
20
Furthermore, blood samples were collected every 2 days to analyze the dynamic characteristics of 21 the virus in these challenged pigs. Notably, the levels of viral RNA were higher in the NTG pigs 22 than in the TG pigs ( Fig. 5D ), suggesting that the TG pigs could effectively alter the dynamic 1 characteristics of the viral infection. The antibody response in the challenged pigs was further 2 measured every 4 days until day 16 ( Fig. 5E ), results showed that the antibody response in the 3 NTG pigs was higher than the TG group. More importantly, compared to the NTG pigs, the 4 antibody response in the TG pigs was delayed by 4~5 days. Meanwhile, compared to the NTG 5 pigs, we found that viral RNA maintained lower levels of expression in CSF susceptible tissues 6 from the TG pigs ( Fig. 5F ). Additionally, we found that the average times to the initial 7 CSFV-associated clinical manifestation for the NTG and TG were 4 and 8.5 dpi, respectively (S8C reservoirs is a significant challenge. Additionally, the singleness of control strategies based on 4 vaccination may also be a contributing factor. Therefore, there is still a long way to go toward 5 eliminating the virus. As an alternative, breeding anti-CSFV pigs via a genome editing strategy 6 can be a more direct and effective approach. This would facilitate the permanent introduction of 7 novel disease resistance traits into the mass population of production pigs via conventional 8 breeding techniques.
9
Recently developed programmable genome editing (PGE) technologies, such as TALEN and 10 CRISPR/Cas9, have been widely used to produce TG animals. Many gene editing strategies can 11 be used to produce viral disease-resistant pigs, and these approaches include knock-out or 1
In this study, we successfully produced anti-CSFV pigs via the CRISPR/Cas9-based knock-in 2 technology. The in vitro and in vivo viral challenge results demonstrated that these TG pigs 3 exhibited higher resistance to CSFV infection than non-transgenic (NTG) pigs and the acquired 4
RNAi-based antiviral ability in these TG founders could be stably transmitted to their 5 F1-generation offspring. However, even though the extent and severity of clinical signs and viremia 6 were lower in the TG pigs than that in the NTG pigs, some clinic signs and viremia also appeared in the 7 TG pigs. These suggest that the TG pigs combined with other antiviral strategies (systematic 8 prophylactic vaccination, crossing with other type of anti-CSFV pigs, introducing new anti-CSFV 9 features, etc.) can further enhance the antiviral ability. Additionally, we must admit that the animal's 10 "in-contact" infectious model experiment is small-scale and short-term preliminary studies, because the 11 overall number of TG pigs was low. As encouraging as these results are, a longer-term animal 12 challenge study and the interference with viral transmission in TG pigs need further investigation.
13
Furthermore, technically, we demonstrated the production of these TG pigs based on 14 CRISPR/Cas9-mediated homology directed repair (HDR). The antiviral shRNA gene in TG pigs was 15 driven by the endogenous pRosa26 promoter, which is suitable for driving exogenous gene 16 expression in a consistent and stable manner by avoiding DNA methylation. Additionally, to reduce 17 the potential risk of drug selection and increase the biological safety of the TG pigs, no selectable 18 maker genes were introduced during the production of the TG pigs. This strategy will help 19 provide market support.
20
Moreover, we believe our antiviral strategy can offers substantial potential benefits over 21 vaccination. The immunization of pigs confers effective protection against CSFV, and the 22 induction of complete clinical protection takes at least 7 days. By that time, the body may 1 become so overrun by infection, and the immune system of the pig may give up trying to battle 2 the infection. In this study, we noticed that the time when the CSFV-associated clinical symptoms 3 began to appear in the TG pigs was significantly delayed (4~5 days) compared with that in the 4 NTG pigs. These finding suggest that these transgenic pigs may have more time to evoke 5 protective immunity and combat the virus. After all, the integrated strategy may be preferred to 6 the singleness of control strategies based on vaccination, and should be considered. Additionally, 7 the CSFV genome is a positive-sense, single-stranded RNA, and it functions as both messenger 8 RNA (mRNA) and a replication template. This TG pig and transgenic strategy can provide some 9 attractive resources to scientists and will help them to better understand and study RNAi.
10
In summary, we report the combinational application of CRISPR/Cas9 and RNAi in the 11 generation of anti-CSFV TG pigs. We confirmed that these TG pigs could limit the growth of 12 CSFV in vivo and in vitro and that the disease resistance traits in the TG founders can be stably 13 transmitted to their F1-generation offspring. This study suggests that these TG pigs can improve 14 the well-being of livestock and contribute to offer potential benefits over commercial vaccination.
15
The use of these TG pigs can improve the well-being of livestock and substantially reduce 16 CSFV-related economic losses. Additionally, we hope the antiviral approach mentioned in this 17 study will provide some references for future antiviral research. were examined using a fluorescence microscope Eclipse TE2000-V (Nikon Imaging, Japan).
30
Plasmids 31 sgRNAs that targeted the pROSA26 locus were designed using online software, and sgRNA 32 oligonucleotides were annealed and cloned into the PX330 vector (42230, Addgene) using the 
38
The donor vector contained a 0.5 kb left homology arm (HA) and a 1.0 kb right HA 39 (Supplemental Figure S3 ). The HAs were amplified by genomic PCR and cloned into the PUC57 40 vector. The shRNA gene was subsequently inserted between the right and left arms. 
33
DNA was isolated from the TG piglet and WT pig tissues and digested with BamHI. shRNA 34 donor vector was used as a positive control. The probe was hybridized to a 20.424-kb fragment,
35
which is depicted in Figure 2B , indicating site-specific gene insertion. The copy number of antiviral shRNA gene was determined by qPCR as previously described [38] .
20
Briefly, a standard curve was produced with series of standard samples containing 0, 1, 2, 4, 8, 10 21 copies of the shRNA gene, respectively, by mixing the wild-type genome of pig with shRNA 22 expression vector. The absolute quantitative standard curve was drawn by plotting 23 ÄCt=Ct shRNA −Ct TFRC against the log of shRNA gene copies of corresponding standard samples.
25 Viral challenge assay in TG cells
26
The in vitro viral challenge assay was strictly performed at a designated safe place. TG fibroblasts,
27
TG kidney cells and TG umbilical vein endothelial cells were isolated from newborn TG pigs.
28
These cells, cultured in 24-well plates, were inoculated with 200 TCID 50 of CSFV (Shimen strain), Table 2) . The KI-1 primers were used to determine 7 homozygosity or heterozygosity, the KI-2 primers amplified the 5-junction, and the KI-3 primers 
38
Pigs 0042, 0047, 0049, 0050, 0058 and 0059 were TG, and pigs 0041, 0044, 0045, 0060 and 0061 were also observed in lymphoid tissue. 14
